company-logoVyant Bio, Inc.$0.19
%
Analyst Rating: Hold

Stock Details

CEO

Andrew D.C. LaFrence CPA

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

4

Address

2 Executive Campus, Cherry Hill, NJ, 08002

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Top Competitors

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Vyant Bio, Inc.  $0.19

$0

Min Forecast(+0% )

$249.61

Avg Forecast( +0% )

$325

Max Forecast(+0%)

EPS

Revenue

Institutional Holder

Loading institutional holder data...

Congress Tracker 

    Showing 0 of 0 results

    Insider Trading of Key Employees

      Showing 0 of 0 results

      Financial News: VYNT